A important advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and offers a https://health-lists.com/story22152291/significant-approach-tirzepatide-45mg-for-blood-sugar-management